AzTrials
AzTrials

Cardio-Renal SyndromeNCT05050877

Risk Factors and Prognosis of Adverse Cardiovascular and Kidney Events After Coronary Intervention II

An observational study of Cardio-Renal Syndrome and Coronary Angiography, run by Guangdong Provincial People's Hospital at 1 site in China.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

As a multi-center, retrospective observation study in southern China, this study included the main study population of patients who underwent coronary angiography at 5 hospitals from Guangzhou, Shenzhen, Yangjiang, Maoming and Longyan from January 2000 to Decemeber 2020. Read more about this study

Who is it for?
Any age
How many people
184,855 participants
Where
1 siteChina
Study dates
1 Jun 2000to 31 Dec 2020
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: The investigators reviewed all consecutive patients who were undergoing coronary angiography.

Who may be able to join

  • 1. Patients referred to CAG or PCI;

Who cannot join

  • -

Trial locations and contacts

1 site in 1 country.

China1 site

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, 510080

Other trials in China

About this study

Official title: Risk Factors and Prognosis of Adverse Cardiovascular and Kidney Events After Coronary Intervention - Cardiorenal ImprovemeNt Registry II

As a multi-center, retrospective observation study in southern China, this study included the main study population of patients who underwent coronary angiography at 5 hospitals from Guangzhou, Shenzhen, Yangjiang, Maoming and Longyan from January 2000 to Decemeber 2020. The hospitalization information was collected in the form of direct derivation of the case, and cardiac and renal adverse events were collected through outpatient system. Data on all-cause death were obtained from the Guangdong Provincial Public Security and matched to the electronic Clinical Management System of the Guangdong Provincial People's Hospital records.

Read the detailed description

This is a multi-center, retrospective observation study collecting data on 184855 coronary angiography patients from January 2000 to Decemeber 2020. Data regarding demographic information, admission diagnoses and history of present illness, biomarkers and details on preventive hydration and medications will be collected. The primary endpoint of this study is Adverse Cardiovascular and Kidney Events.

Keywords
contrast-induced acute kidney injury, contrast medium, creatinine clearance, coronary angiography, chronic kidney disease, Adverse Cardiovascular and Kidney Events
Medical subject headings
Cardio-Renal Syndrome, Coronary Artery Disease, Kidney Diseases, Metabolic Syndrome, Renal Insufficiency, Chronic

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT05050877
Study groupRoleWhat they receive
coronary angiographyThe investigators recruit all consecutive patients who were undergoing coronary angiography or percutaneous coronary intervention.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Contrast-Induced Acute Kidney Injury (CI-AKI 0.3)

    defined as a ≥ 0.3 mg/dL absolute increase in serum creatinine from baseline during the first 48 hours after the procedure

    Measured: 48 hours

Secondary outcomes (2)

  1. Cystatin C based CI-AKI (CI-AKI cyc)

    Cystatin C based CI-AKI, defined as a ≥10% absolute increase in serum cystatin C during the first 24 hours after the procedure and and a ≥ 0.3 mg/dL absolute increase in serum creatinine from baseline during the first 48 hours after the procedure.mg/dL absolute increase in serum creatinine from baseline during the first 48 hours after the procedure.

    Measured: 24-48 hours

  2. The change of eGFR, calculate based on CrCl and serum cystatin C

    The eGFR creatinine-cystatin C was calculated by the 2012 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) cystatin C equation: 135 *min(Scr/κ, 1)α * max(Scr/κ, 1)-0.601 * min(Scys/0.8, 1)-0.375 * max (Scys/0.8, 1)-0.711 * 0.995Age [* 0.969 if female] [* 1.08 if black], where Scr is serum creatinine, Scys is serum cystatin C, κ is 0.7 for females and 0.9 for males, α is -0.248 for females and -0.207 for males, min indicates the minimum of Scr/κ or

    1, and max indicates the maximum of Scr/κ or 1.

    Measured: 48-72 hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Sep 2021
  2. Study start1 Jun 2000
  3. Primary completion31 Dec 2020
  4. Study completion31 Dec 2020

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Retrospective
Enrolment
184,855 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05050877
Sponsor's protocol ID
2019-555H-2
Status last verified
Sep 2021
First submitted
9 Sep 2021
Last updated
21 Sep 2021
Results posted
No
Data monitoring committee
Yes
Individual data sharing
Undecided

Publications

  • Chen J, Lu X, Ruan X, Li Z, Aji Y, Mohsen AAFA, Guo W, Chen J, Chen S, Xu J, Liu J, Liu Y. Lipoprotein(a) and Prognostic Nutritional Index Levels Exhibit Interactive and Joint Effects on Mortality Risk in Patients With Coronary Artery Disease: Findings From a Real-World Study. Rev Cardiovasc Med. 2026 Oct 16;27(10):51948. doi: 10.31083/RCM51948. eCollection 2026 Oct.

    PubMed 42985587

  • Pan W, Lu X, Zhou Z, Liu J, Zhang S, Huang H, He Y, Deng J, Ling Y, Ruan X, Jing L, Zhang W, Chen S, Liao X, Chen J, Zhuang X, Liu Y. Excess apolipoprotein B predicts long-term survival in statin-treated CAD irrespective of achieved LDL-C levels: a pooled cohort analysis. Lipids Health Dis. 2026 Mar 24;25(1):124. doi: 10.1186/s12944-026-02928-z.

    PubMed 41877106

  • Liu J, Ruan H, Lu X, Ye W, Huang H, Tang S, Yuan Z, Huang Z, Chen S, Tan N, Chen J, Liu Y. Systemic inflammation affects the association between pericoronary fat attenuation index and adverse cardiovascular risk in patients with coronary artery disease. Int J Cardiovasc Imaging. 2026 Jul;42(7):1289-1300. doi: 10.1007/s10554-026-03662-4. Epub 2026 Feb 23.

    PubMed 41729387

  • Lu X, Wei P, Tang S, Ye W, Huang Z, Yuan Z, Ruan H, Huang H, Zhang W, Wang C, Kang Y, Hu J, Li Z, Deng J, Li Y, Wu W, Ming WK, Wong CK, Tan N, Chen S, Liu J, Chen J, Liu Y. Pericoronary fat attenuation index on coronary CT angiography and cardiovascular risk in patients with coronary artery disease and chronic kidney disease. BMC Nephrol. 2025 Nov 12;26(1):632. doi: 10.1186/s12882-025-04549-7.

    PubMed 41225370

  • Deng L, Chen H, Xu Q, Han K, Liu J, Chen S, Deng J, Tian L, Li Z, Lu X, Liu Y, Liang Y. The High-Sensitivity C-Reactive Protein to High-Density Lipoprotein Cholesterol Ratio and the Risk of Contrast-Induced Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Intervention. Rev Cardiovasc Med. 2024 Sep 23;25(9):338. doi: 10.31083/j.rcm2509338. eCollection 2024 Sep.

    PubMed 39355575

  • Zhou Z, Qiao L, Ling Y, He Y, Chang T, Lu H, Yu S, Liu J, Guo W, Chen S, Liu Y, Chen J. Intermediate Hyperglycemia Increases the Risk of All-Cause Mortality in Premature Coronary Artery Disease Patients Undergoing Percutaneous Coronary Intervention. Rev Cardiovasc Med. 2023 Dec 13;24(12):352. doi: 10.31083/j.rcm2412352. eCollection 2023 Dec.

    PubMed 39077077

  • Xie Y, Xu X, Wang D, Zhou Y, Kang Y, Lai W, Lu H, Liu J, Chen S, Xu J, Yan X, Huang X, Liu Y. Fibrinogen-to-Albumin Ratio and Long-Term Mortality in Coronary Artery Disease Patients with Different Glucose Metabolism Status. Rev Cardiovasc Med. 2023 Nov 16;24(11):317. doi: 10.31083/j.rcm2411317. eCollection 2023 Nov.

    PubMed 39076427

  • Wu W, Jia C, Xu X, He Y, Xie Y, Zhou Y, Lu H, Liu J, Chen J, Liu Y. Impact of Platelet-to-HDL-Cholesterol Ratio on Long-Term Mortality in Coronary Artery Disease Patients with or Without Type 2 Diabetes: Insights from a Chinese Multicenter Cohort. J Inflamm Res. 2024 May 6;17:2731-2744. doi: 10.2147/JIR.S458950. eCollection 2024.

    PubMed 38737110

  • Jia C, Wu W, Lu H, Liu J, Chen S, Liang G, Zhou Y, Yu S, Qiao L, Chen J, Tan N, Liu Y, Chen J. Fibrinogen to HDL-Cholesterol ratio as a predictor of mortality risk in patients with acute myocardial infarction. Lipids Health Dis. 2024 Mar 25;23(1):86. doi: 10.1186/s12944-024-02071-7.

    PubMed 38528580

  • Lu J, He Y, Yang Y, Zhong X, Chen S, Wu B, Pan Y, Wang Y, Xiu J, Kang Y, Liu J, Liu Y, Chen S, Chen K, Chen L. Age-Related Effect of Uric Acid on Contrast-Induced Acute Kidney Injury of Patients Undergoing Coronary Angiography. Clin Interv Aging. 2023 Dec 7;18:2053-2061. doi: 10.2147/CIA.S419370. eCollection 2023.

    PubMed 38088947

  • Liu J, Chen S, Zhou Y, Huang H, Li Q, Liang Y, Dong S, Huang X, Chen L, Zheng X, Meng R, Jia C, Chen J, Tan N, Liu Y. Proportion and number of incident cancer deaths in coronary artery disease. Cancer Med. 2023 Oct;12(19):20140-20149. doi: 10.1002/cam4.6595. Epub 2023 Sep 27.

    PubMed 37754571

  • Liu J, Chen S, Zhou Y, Zheng X, Meng R, Tan N, Liu Y. Effect of cumulative radiation exposure from Coronary catheterization on lung cancer mortality. BMC Cancer. 2023 Aug 15;23(1):757. doi: 10.1186/s12885-023-11231-4.

    PubMed 37582730

  • Gao F, Huang Z, Liang J, Kang Y, Ling Y, He Y, Chen J, Hong D, Zhang Z, Xu S, Wang A, Yan X, Liu J, Liu Y, Chen S, Chen J. Association of malnutrition with all-cause and cardiovascular mortality in patients with mild to severe chronic kidney disease undergoing coronary angiography: a large multicenter longitudinal study. Int Urol Nephrol. 2023 Dec;55(12):3225-3236. doi: 10.1007/s11255-023-03566-5. Epub 2023 Apr 27.

    PubMed 37103656

Questions about this trial

What is this clinical trial studying?

An observational study of Cardio-Renal Syndrome and Coronary Angiography, run by Guangdong Provincial People's Hospital at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 21 Sep 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Contrast-Induced Acute Kidney Injury (CI-AKI 0.3) (time frame: 48 hours). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05050877, which also lists 13 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Sep 2021.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in